Oncternal Therapeutics Inc Cash Flow Conversion Efficiency
Oncternal Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has a cash flow conversion efficiency ratio of -0.760x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.95 Million) by net assets ($9.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncternal Therapeutics Inc (2002–2023)
Cash flow conversion efficiency of Oncternal Therapeutics Inc from 2002 to 2023. This chart illustrates how Oncternal Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ONCT live share price for real-time trading data and today's change.
Oncternal Therapeutics Inc Cash Flow Conversion Ratio Explained
Oncternal Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncternal Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncternal Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market value of Oncternal Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bakrieland Development Tbk
JK:ELTY
|
0.014x |
|
Lypsa Gems & Jewellery Limited
NSE:LYPSAGEMS
|
0.052x |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
|
Avrupa Minerals Ltd
V:AVU
|
-0.155x |
|
Aruma Resources Ltd
AU:AAJ
|
-0.373x |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
-0.119x |
|
Golden Cross Resources Ltd
AU:GCR
|
-0.046x |
|
Innovation Beverage Group Limited
NASDAQ:IBG
|
-0.413x |
Annual Cash Flow Conversion Efficiency for Oncternal Therapeutics Inc (2002–2023)
The table below shows the annual cash flow conversion efficiency of Oncternal Therapeutics Inc from 2002 to 2023. Review Oncternal Therapeutics Inc (ONCT) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $30.05 Million | $-32.16 Million | -1.070x | -77.78% |
| 2022-12-31 | $60.97 Million | $-36.70 Million | -0.602x | -99.52% |
| 2021-12-31 | $88.12 Million | $-26.59 Million | -0.302x | -94.81% |
| 2020-12-31 | $112.95 Million | $-17.50 Million | -0.155x | +86.76% |
| 2019-12-31 | $14.31 Million | $-16.75 Million | -1.170x | +22.35% |
| 2018-12-31 | $26.11 Million | $-39.35 Million | -1.507x | -145.76% |
| 2017-12-31 | $38.26 Million | $-23.46 Million | -0.613x | +41.30% |
| 2016-12-31 | $19.89 Million | $-20.78 Million | -1.045x | +90.31% |
| 2015-12-31 | $1.86 Million | $-20.04 Million | -10.777x | -568.13% |
| 2014-12-31 | $17.83 Million | $-28.76 Million | -1.613x | +60.81% |
| 2013-12-31 | $10.68 Million | $-43.97 Million | -4.116x | -429.03% |
| 2012-12-31 | $47.70 Million | $-37.11 Million | -0.778x | -68.98% |
| 2011-12-31 | $71.87 Million | $-33.09 Million | -0.460x | +21.99% |
| 2010-12-31 | $51.73 Million | $-30.53 Million | -0.590x | -111.23% |
| 2009-12-31 | $-8.75 Million | $-46.00 Million | 5.257x | +5854.26% |
| 2008-12-31 | $32.02 Million | $-2.92 Million | -0.091x | +80.84% |
| 2007-12-31 | $78.92 Million | $-37.63 Million | -0.477x | -303.85% |
| 2006-12-31 | $97.05 Million | $-11.46 Million | -0.118x | +75.05% |
| 2005-12-31 | $73.58 Million | $-34.82 Million | -0.473x | -92.99% |
| 2004-12-31 | $63.91 Million | $-15.67 Million | -0.245x | -383.43% |
| 2003-12-31 | $-150.23 Million | $-13.00 Million | 0.087x | -54.66% |
| 2002-12-31 | $-55.31 Million | $-10.55 Million | 0.191x | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more